Study summary

Parts A & B: Conversion of stable pediatric allograft recipients from Prograf® immunosuppression to Advagraf® immunosuppression to compare exposure and one year follow-up for safety and efficacy.

Part C: Continuation of long-term follow-up and provision of ongoing study medication to subjects to whom Advagraf® is currently not available.

Additional Study Details

Phase
Phase 2
Product
tacrolimus
Product
Tacrolimus
Tacrolimus prolonged release
Type
Interventional
Masking
None (Open Label)
Enrollment number
81
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Scientific Results Summary 2
Available Language(s): English
Plain Language Summary
Available Language(s): English, Czech, Dutch, French, Italian, German, Polish

Get more information

Would you like more information about clinical trial sites that are recruiting participants for Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from Prograf® to Advagraf®? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site FR33
    Paris Cedex 15, France, 75908
    Withdrawn
    Site IT71
    Rome, Italy, 165
    Withdrawn
    Site AT11
    Vienna, Austria, 1090
    Completed
    Site CZ42
    Prague 5, Czech Republic, 150 06
    Completed
    Site FR32
    Paris Cedex 15, France, 75743
    Completed
    Site IT75
    Palermo, Italy, 90127
    Withdrawn
    Site IT73
    Padova, Italy, 35128
    Completed
    Site DE41
    Heidelberg, Germany, 69120
    Completed
    Site FR35
    BRON Cedex, France, 69677
    Completed
    Site GB62
    Birmingham, United Kingdom, B4 6NH
    Completed
    Site BE21
    Brussels, Belgium, 1020
    Completed
    Site GB64
    London, United Kingdom, WC1 3JH
    Withdrawn
    Site IT72
    Rome, Italy, 00165
    Completed
    Site IT74
    Bergamo, Italy, 24127
    Completed
    Site GB61
    Manchester, United Kingdom, M27 4HA
    Completed
    Site FR31
    Paris Cedex 15, France, 75743
    Completed
    Site PL52
    Warsaw, Poland, 04-730
    Completed
    Site PL51
    Warsaw, Poland, 04-730
    Completed
    Site BE22
    Brussels, Belgium, 1200
    Completed
    Site FR34
    Bron Cedex, France, 69677

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?